Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares LG, Gainor JF, Ahmed S, Reck M, Maio M, O'Byrne KJ, Memaj A, Nathan F, Tran P, Hellmann MD, Brahmer JR. Borghaei H, et al. Among authors: ciuleanu te. Ann Oncol. 2023 Feb;34(2):173-185. doi: 10.1016/j.annonc.2022.11.006. Epub 2022 Nov 19. Ann Oncol. 2023. PMID: 36414192 Free article.
Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey.
Gheorghe AS, Negru ŞM, Nițipir C, Mazilu L, Marinca M, Gafton B, Ciuleanu TE, Schenker M, Dragomir RD, Gheorghe AD, Stovicek PO, Bandi-Vasilica M, Boț AC, Mihăilă RI, Zob DL, Kajanto AL, Stănculeanu DL. Gheorghe AS, et al. Among authors: ciuleanu te. ESMO Open. 2021 Feb;6(1):100027. doi: 10.1016/j.esmoop.2020.100027. Epub 2020 Dec 2. ESMO Open. 2021. PMID: 33399089 Free PMC article.
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Goodwin R, Ding K, Seymour L, LeMaître A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM, Laurie SA; from the NCIC Clinical Trials Group, Kingston, Ontario, Canada. Goodwin R, et al. Ann Oncol. 2010 Nov;21(11):2220-2226. doi: 10.1093/annonc/mdq221. Epub 2010 Apr 28. Ann Oncol. 2010. PMID: 20427348 Free article. Clinical Trial.
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.
Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold C, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC; Central European Cooperative Oncology Group (CECOG). Brodowicz T, et al. Ann Oncol. 2012 May;23(5):1223-1229. doi: 10.1093/annonc/mdr381. Epub 2011 Sep 22. Ann Oncol. 2012. PMID: 21940784 Free article.
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Smit EF, Socinski MA, Mullaney BP, Myrand SP, Scagliotti GV, Lorigan P, Reck M, Ciuleanu T, von Pawel J, Karaseva NA, Szczesna A, Ohannesian D, Powell E, Hozak RR, Hong S, Guba SC, Thatcher N. Smit EF, et al. Ann Oncol. 2012 Jul;23(7):1723-9. doi: 10.1093/annonc/mdr563. Epub 2011 Dec 19. Ann Oncol. 2012. PMID: 22186609 Free article.
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, Middleton G, Zeaiter A, Klingelschmitt G, Klughammer B, Thatcher N. Ciuleanu T, et al. Lung Cancer. 2013 Nov;82(2):276-81. doi: 10.1016/j.lungcan.2013.08.002. Epub 2013 Aug 13. Lung Cancer. 2013. PMID: 23992877 Free article. Clinical Trial.
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D. Ramalingam S, et al. Ann Oncol. 2015 Aug;26(8):1741-8. doi: 10.1093/annonc/mdv220. Epub 2015 May 21. Ann Oncol. 2015. PMID: 25997818 Free article. Clinical Trial.
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W. Ciuleanu T, et al. Ann Oncol. 2016 Apr;27(4):680-7. doi: 10.1093/annonc/mdw004. Epub 2016 Jan 22. Ann Oncol. 2016. PMID: 26802147 Free article. Clinical Trial.
101 results